Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110

finance.yahoo.com/news/mizuho-reiterates-outperform-rating-insmed-145302888.html

In This Article:
Insmed Inc. (NASDAQ:INSM) is one of the 10 best growth stocks to buy according to billionaires. On June 10, Mizuho analyst Graig Suvannavejh reaffirmed his Outperform rating on Insmed and raised the price target from $96 to $110. The revision follows the encouraging…

This story appeared on finance.yahoo.com, 2025-06-18 14:53:02.
The Entire Business World on a Single Page. Free to Use →